Impact of CYP3A5 polymorphism on trough plasma concentrations of darunavir when co-administred with etravirine in a cohort of HIV-1 infected patients

Belkhir, Leïla; Elens, Laure; Zech, Francis; Vandercam, Bernard; Haufroid, Vincent

Impact of CYP3A5 polymorphism on trough plasma concentrations of darunavir when co-administred with etravirine in a cohort of HIV-1 infected patients

Belkhir, Leïla

;

Elens, Laure

;

Zech, Francis

;

Vandercam, Bernard

;

Haufroid, Vincent

(2016) IREC 3rd PhD Day — Location: (Belgium) Bruxelles (4.March.2016)

Files

No attached file found for this publication.

Details

Authors

Belkhir, LeïlaUCLouvain
Author
Elens, LaureUCLouvain
Author
Zech, FrancisUCLouvain
Author
Vandercam, BernardUCLouvain
Author
Haufroid, VincentUCLouvain
Author

Affiliations

UCLouvainSSS/IREC - Institut de recherche expérimentale et clinique
UCLouvainSSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology
UCLouvainSSS/LDRI - Louvain Drug Research Institute
UCLouvain(SLuc) Service de biochimie médicale
UCLouvain(SLuc) Service de médecine interne et maladies infectieuses (MIMI)

Citations

APA
Chicago
FWB

Belkhir, L., Elens, L., Zech, F., Vandercam, B., & Haufroid, V. (2016). Impact of CYP3A5 polymorphism on trough plasma concentrations of darunavir when co-administred with etravirine in a cohort of HIV-1 infected patients. IREC 3rd PhD Day, (Belgium) Bruxelles. https://hdl.handle.net/2078.5/183275